Literature DB >> 8513655

Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.

D G Bailey1, J M Arnold, C Munoz, J D Spence.   

Abstract

Grapefruit juice produces a marked and variable increase in felodipine bioavailability. The pharmacokinetics of felodipine and its single primary oxidative metabolite, dehydrofelodipine, were studied after drug administration with 200 ml water, grapefruit juice, or naringin in water at the same concentration as the juice in a randomized crossover trial of nine healthy men. With grapefruit juice, mean +/- SEM felodipine area under the plasma concentration-time curve (AUC) and peak plasma concentration (Cmax) were 206% +/- 23% (range, 123% to 330%, p < 0.01) and 170% +/- 24% (range, 127% to 310%, p < 0.02), respectively, compared with water. Dehydrofelodipine/felodipine ratios for AUC (1.5 +/- 0.2 versus 2.2 +/- 0.2, p < 0.001) and felodipine Cmax (1.5 +/- 0.2 versus 2.2 +/- 0.2, p < 0.001) were reduced, consistent with inhibition of presystemic felodipine metabolism. Intersubject changes in felodipine and dehydrofelodipine AUC supported inhibition of both primary and secondary metabolic steps as a mechanism. The interaction could not be predicted from baseline pharmacokinetics with water and did not result in more consistent bioavailability among individuals. Naringin solution produced much less of an interaction, showing that other factors were important.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513655     DOI: 10.1038/clpt.1993.84

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  43 in total

1.  Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.

Authors:  H Takanaga; A Ohnishi; H Matsuo; H Murakami; H Sata; K Kuroda; A Urae; S Higuchi; Y Sawada
Journal:  Br J Clin Pharmacol       Date:  2000-01       Impact factor: 4.335

2.  Influence of low-dose oral contraceptives, alcohol, and grapefruit on.

Authors:  H Van Vlierberghe; F Van Durme; H Verdievel; M Dhont; M de Vos; A Elewaut
Journal:  Dig Dis Sci       Date:  2001-01       Impact factor: 3.199

3.  Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms.

Authors:  Wenjie Jessie Lu; Valentina Ferlito; Cong Xu; David Alastair Flockhart; Salvatore Caccamese
Journal:  Chirality       Date:  2011-09-22       Impact factor: 2.437

Review 4.  Influence of dietary substances on intestinal drug metabolism and transport.

Authors:  Christina S Won; Nicholas H Oberlies; Mary F Paine
Journal:  Curr Drug Metab       Date:  2010-11       Impact factor: 3.731

Review 5.  Fruit juice inhibition of uptake transport: a new type of food-drug interaction.

Authors:  David G Bailey
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

6.  Major determinant factors of the extent of interaction between grapefruit juice and calcium channel antagonists.

Authors:  Ayako Ohnishi; Hisakazu Ohtani; Yasufumi Sawada
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

7.  Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?

Authors:  Bui Tri Cuong; Vu Quoc Binh; Bui Dai; Dinh Ngoc Duy; Claire M Lovell; Karl H Rieckmann; Michael D Edstein
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

Review 8.  Grapefruit juice-drug interactions.

Authors:  D G Bailey; J Malcolm; O Arnold; J D Spence
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

9.  In vitro inhibition of midazolam and quinidine metabolism by flavonoids.

Authors:  H R Ha; J Chen; P M Leuenberger; A U Freiburghaus; F Follath
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  The effects of pummelo juice on pharmacokinetics of sildenafil in healthy adult male Jordanian volunteers.

Authors:  Mutasim A Al-Ghazawi; Maha S Tutunji; Salah M AbuRuz
Journal:  Eur J Clin Pharmacol       Date:  2009-10-15       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.